IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences [Yahoo! Finance]
Clene Inc. (CLNN)
Company Research
Source: Yahoo! Finance
LOS ANGELES, CA - ( NewMediaWire ) - October 21, 2024 - Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") multiple sclerosis ("MS") and Parkinson's Disease ("PD"), is participating in two top investor conferences this month to present its latest achievements and key updates on its lead drug candidate, CNM-Au8 ( https://ibn.fm/BDqtM Clene gave a fireside presentation and held one-on-one investor meetings at the 2024 Maxim Healthcare Virtual Summit on October 15. On October 30, Clene will give a presentation and participate in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York. Clene's lead drug candidate, CNM-Au8 (R) has been shown to restore and protect neurological function, offering new hope for p
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- Clene Inc. (NASDAQ: CLNN) had its price target lowered by analysts at Benchmark Co. from $90.00 to $84.00. They now have a "buy" rating on the stock.MarketBeat
- Clene Inc. (NASDAQ: CLNN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $83.00. They now have a "buy" rating on the stock.MarketBeat
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $31.00 price target on the stock.MarketBeat
- Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Clene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsGlobeNewswire
CLNN
Earnings
- 11/13/24 - Beat
CLNN
Sec Filings
- 11/22/24 - Form 424B3
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- CLNN's page on the SEC website